Program
CSL300
A development code.
Its studies are mostly in Kidney Failure, Chronic, led by CSL.
Furthest: phase 3, since Jul 29, 20222 company-led studies, 2 open or runningNext primary completion: Aug 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSL | 22 open or running | phase 3since Jul 29, 2022 | Jul 29, 2022 | Aug 30, 2027phase 1 · NCT07619820 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 29, 2022First study: phase 3 study in Kidney Failure, ChronicFirst studyNCT05485961 · 3,110 planned · United States, Argentina, Australia and more
- May 26, 2026Phase 1 study in Kidney Failure, ChronicNCT07619820 · 24 planned · China
Ahead
- Aug 30, 2027Primary completion: phase 1 study in Kidney Failure, ChronicNCT07619820
- May 22, 2029Primary completion: phase 3 study in Kidney Failure, ChronicNCT05485961
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07619820Kidney Failure, Chronic · China | 1 | Recruiting | Aug 30, 2027 | 24 |
| NCT05485961Kidney Failure, Chronic · United States, Argentina, Australia and more | 3 | Recruiting | May 22, 2029 | 3,110 |
How it is read
Names in the registry
- “CSL300”, 2 entries
Codes read as this program: CSL300.
Conditions, from the studies’ own filings
- Kidney Failure, Chronic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.